Stock Scorecard
Stock Summary for Axsome Therapeutics Inc (AXSM) - $109.22 as of 8/18/2025 12:13:25 PM EST
Total Score
6 out of 30
Safety Score
45 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AXSM
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AXSM
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AXSM
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AXSM
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AXSM (45 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for AXSM
Financial Details for AXSM
Company Overview |
|
|---|---|
| Ticker | AXSM |
| Company Name | Axsome Therapeutics Inc |
| Country | USA |
| Description | Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/10/2025 |
Stock Price History |
|
| Last Day Price | 109.22 |
| Price 4 Years Ago | 37.78 |
| Last Day Price Updated | 8/18/2025 12:13:25 PM EST |
| Last Day Volume | 383,874 |
| Average Daily Volume | 632,552 |
| 52-Week High | 139.13 |
| 52-Week Low | 75.56 |
| Last Price to 52 Week Low | 44.55% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.35 |
| Sector PE | 59.06 |
| 5-Year Average PE | -20.99 |
| Free Cash Flow Ratio | 17.99 |
| Industry Free Cash Flow Ratio | 15.81 |
| Sector Free Cash Flow Ratio | 30.26 |
| Current Ratio Most Recent Quarter | 1.57 |
| Total Cash Per Share | 6.07 |
| Book Value Per Share Most Recent Quarter | 1.47 |
| Price to Book Ratio | 74.26 |
| Industry Price to Book Ratio | 31.11 |
| Sector Price to Book Ratio | 26.93 |
| Price to Sales Ratio Twelve Trailing Months | 10.96 |
| Industry Price to Sales Ratio Twelve Trailing Months | 34.46 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.21 |
| Analyst Buy Ratings | 14 |
| Analyst Strong Buy Ratings | 5 |
Share Statistics |
|
| Total Shares Outstanding | 49,901,500 |
| Market Capitalization | 5,450,241,830 |
| Institutional Ownership | 76.40% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -20.05% |
| Reported EPS 12 Trailing Months | -5.06 |
| Reported EPS Past Year | -2.19 |
| Reported EPS Prior Year | -5.99 |
| Net Income Twelve Trailing Months | -246,900,000 |
| Net Income Past Year | -287,216,000 |
| Net Income Prior Year | -239,238,000 |
| Quarterly Revenue Growth YOY | 72.10% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -29.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 303,016,000 |
| Total Cash Past Year | 315,353,000 |
| Total Cash Prior Year | 386,193,000 |
| Net Cash Position Most Recent Quarter | 185,476,000 |
| Net Cash Position Past Year | 134,643,000 |
| Long Term Debt Past Year | 180,710,000 |
| Long Term Debt Prior Year | 178,070,000 |
| Total Debt Most Recent Quarter | 117,540,000 |
| Equity to Debt Ratio Past Year | 0.24 |
| Equity to Debt Ratio Most Recent Quarter | 0.38 |
| Total Stockholder Equity Past Year | 57,015,000 |
| Total Stockholder Equity Prior Year | 190,977,000 |
| Total Stockholder Equity Most Recent Quarter | 73,075,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -121,162,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.43 |
| Free Cash Flow Past Year | -128,680,000 |
| Free Cash Flow Prior Year | -145,662,000 |
Options |
|
| Put/Call Ratio | 0.10 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.23 |
| MACD Signal | -0.61 |
| 20-Day Bollinger Lower Band | 97.50 |
| 20-Day Bollinger Middle Band | 105.45 |
| 20-Day Bollinger Upper Band | 113.40 |
| Beta | 0.51 |
| RSI | 56.91 |
| 50-Day SMA | 102.58 |
| 150-Day SMA | 82.38 |
| 200-Day SMA | 71.16 |
System |
|
| Modified | 8/15/2025 6:16:48 PM EST |